- Home
- DRMA vs KZIA Comparison
DRMA vs KZIA Comparison
Compare DRMA & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRMA
- KZIA
- Stock Information
- Founded
- DRMA 2014
- KZIA 1994
- Country
- DRMA United States
- KZIA Australia
- Employees
- DRMA N/A
- KZIA N/A
- Industry
- DRMA Biotechnology: Pharmaceutical Preparations
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- DRMA Health Care
- KZIA Health Care
- Exchange
- DRMA Nasdaq
- KZIA Nasdaq
- Market Cap
- DRMA 4.5M
- KZIA 5.1M
- IPO Year
- DRMA 2021
- KZIA 1999
- Fundamental
- Price
- DRMA $0.75
- KZIA $5.65
- Analyst Decision
- DRMA Strong Buy
- KZIA Strong Buy
- Analyst Count
- DRMA 1
- KZIA 2
- Target Price
- DRMA $3.00
- KZIA $57.50
- AVG Volume (30 Days)
- DRMA 70.9K
- KZIA 24.0K
- Earning Date
- DRMA 05-14-2025
- KZIA 06-17-2025
- Dividend Yield
- DRMA N/A
- KZIA N/A
- EPS Growth
- DRMA N/A
- KZIA N/A
- EPS
- DRMA N/A
- KZIA N/A
- Revenue
- DRMA N/A
- KZIA $1,655,324.00
- Revenue This Year
- DRMA N/A
- KZIA N/A
- Revenue Next Year
- DRMA N/A
- KZIA N/A
- P/E Ratio
- DRMA N/A
- KZIA N/A
- Revenue Growth
- DRMA N/A
- KZIA 248000.00
- 52 Week Low
- DRMA $0.66
- KZIA $2.86
- 52 Week High
- DRMA $5.00
- KZIA $79.00
- Technical
- Relative Strength Index (RSI)
- DRMA 44.67
- KZIA 78.10
- Support Level
- DRMA $0.66
- KZIA $3.54
- Resistance Level
- DRMA $0.75
- KZIA $4.00
- Average True Range (ATR)
- DRMA 0.05
- KZIA 0.50
- MACD
- DRMA 0.00
- KZIA 0.25
- Stochastic Oscillator
- DRMA 44.50
- KZIA 86.07
About DRMA Dermata Therapeutics Inc.
Dermata Therapeutics Inc. is a clinical-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, DMT310 and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.